Part-I - Controller General of Patents Designs and Trademarks

(12) PATENT APPLICATION PUBLICATION (21) Application No.2415/MUM/2010 A
(19) INDIA
(22) Date of filing of Application :30/08/2010 (43) Publication Date : 21/06/2013
(54) Title of the invention : ANTIUROLITHIATIC ACTIVITY OF A POLYHERBAL PRODUCT UNEX
(51) International classification
:A61k
36/00
(31) Priority Document No :NA
(32) Priority Date :NA
(33) Name of priority country :NA
(86) International Application No
:NA
Filing Date
:NA
(87) International Publication No : NA
(61) Patent of Addition to Application Number :NA
Filing Date
:NA
(62) Divisional to Application Number
:NA
Filing Date
:NA
(71)Name of Applicant :
1)UNIJULES LIFE SCIENCES LTD.
Address of Applicant :NO. 1505/1, UNIVERSAL SQUARE
SHANTINAGAR, NAGPUR, MAHARASHTRA, INDIA.
(72)Name of Inventor :
1)SHOWKAT AHMAD PATNI
2)ANWAR SIRAJ DAUD
3)SHAMSUDDIN JAMALLUDIN
4)SUHAIL ASGHAR
5)GUPTA VIPIN BIHARI
6)EDWIN JARALD
7)PANKAJ KUSHWAH
(57) Abstract :
Abstract of invention (Not applicable in case of provisional specification. Separate sheet to be used for this column.)e
antiurolithiatic activity of a polyherbal formulation, Unex. Urolithiasis or form The present invention relates to thation of urinary
calculi at any level of the urinary tract is a common condition and are characterized clinically by colicky pain. The present
invention relates with the discovery of one polyherbal product, Unex manufactured by Unijules Life Sciences Ltd., and Associated
Companies, Nagpur, containing the extracts of Boerrhavia diffusa and Tribulus terrestris in the ratio of 2:1, which has been found
effective in prevention of formation of kidney stones. The capsules containing the extracts of both the herbs were procured from
the Unijules Life Sciences Ltd., and Associated Companies, Nagpur. A study was conducted to determine the effect of Unex in
kidney stone formation using Ethylene glycol induced model. Cystone 750 mg/kg was used as the standard drug to compare the
efficacy of Unex. Five groups containing 6 animals in each group were subjected to 0.75% ethylene glycol into drinking water for
four weeks and the sixth group was kept as normal control. 15 day onwards till 28! day Unex in two doses, 200 and 400 mg/kg,
and cystone were given to three groups of animals. Remaining one group served as negative control, untreated. On 29th day the
urine of animals was analyzed for calcium, phosphate and oxalate. Serum was analyzed for creatinine, uric acid and urea nitrogen.
Urinary volume was measured by using measuring cylinder, and reported in ml. Uric acid crystals were found to deposit most
frequently in the concentrated acid urine. Thus the acidity of the urine was also tested using pH meter. Results indicated that the
capsule Unex prevented the rise of Oxalate, calcium and phosphate which are the main markers of urolithiasis (Table 1). Stone
formation leads to the increased levels of blood urea nitrogen, creatinine and uric acid. Treatment with Unex has restored these
values significantly (Table 2). The low dose of Unex was found better active. Increased urinary output was identified in the Unex
treated group, which confirms its activity as diuretic. Unex has prevented the rise in pH of treated group when compared to model
control group
No. of Pages : 6 No. of Claims : 5
The Patent Office Journal 21/06/2013 13612